Sugi Predict

Sugi Predict / Compounds / SCHEMBL31326421

SCHEMBL31326421

SCHEMBL31326421

COc1nc(Cl)ncc1N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ STK17B O94768 1/20 0.38
▸ STK17A Q9UEE5 1/20 0.38
▸ SYK P43405 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ ATF1 P18846 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ PIN1 Q13526 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.31
▸ MT-CO2 P00403 1/20 0.31
▸ ATR Q13535 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12367233 0.84 STK17B (0.40) STK17BSTK17ASYKATF1NFKB1
SCHEMBL12303887 0.83 SYK (0.40) STK17BSTK17ASYKATF1NFKB1
SCHEMBL26647074 0.78 ALDH1A1 (0.38) STK17BSTK17ASYKALDH1A1GAA
SCHEMBL30068217 0.78 ALDH1A1 (0.38) STK17BSTK17ASYKALDH1A1GAA
SCHEMBL17133463 0.76 CKS1B (0.41) STK17BSTK17ASYKALDH1A1NFKB1
SCHEMBL30068021 0.76 CCR4 (0.36) STK17BSTK17ASYKUSP30ATR
SCHEMBL26646973 0.76 CCR4 (0.36) STK17BSTK17ASYKUSP30ATR
SCHEMBL25323395 0.75 STK17B (0.45) STK17BSTK17ASYKATF1NFKB1
SCHEMBL30550836 0.75 STK17B (0.45) STK17BSTK17ASYKATF1NFKB1
SCHEMBL12332862 0.75 SYK (0.38) STK17BSTK17ASYKNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612402-B2 Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) 2026-04-28 — — US disclosed
US-20250304578-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) 2025-10-02 — — US disclosed
CN-119350323-B N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof 上海宇道生物技术有限公司 2025-06-13 — — CN disclosed
CN-119350323-A N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof 上海宇道生物技术有限公司 2025-01-24 — — CN disclosed
WO-2025011684-A2 N-SULFONAMIDE NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND APPLICATION THEREOF 上海宇道生物技术有限公司 2025-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304578-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF TP53, NPM1, TP53BP1 STK17B 1142/4885STK17A 1127/4885SYK 448/4885
US-12612402-B2 Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 STK17B 1790/4885STK17A 1976/4885SYK 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.